NCT06134648View on ClinicalTrials.gov

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

646

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

March 10, 2026

Study Completion Date

March 10, 2026

Conditions
Respiratory Syncytial Virus InfectionHealthy VolunteersHuman Metapneumovirus
Interventions
BIOLOGICAL

RSV/hMPV vaccine candidate Dose L

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

BIOLOGICAL

RSV/hMPV vaccine candidate Dose A

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

BIOLOGICAL

RSV/hMPV vaccine candidate Dose B

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

BIOLOGICAL

Placebo

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Trial Locations (13)

33173

Suncoast Research Associates, LLC Site Number : 8400002, Miami

37919

AMR Knoxville Site Number : 8400010, Knoxville

40509

AMR Lexington Site Number : 8400008, Lexington

51106

Velocity Clinical Research, Sioux City Site Number : 8400012, Sioux City

60181

AMR Chicago, Oakbrook Terrace Site Number : 8400019, Oakbrook Terrace

64114

AMR Kansas City Site Number : 8400014, Kansas City

77375

DM Clinical Research - Tomball Site Number : 8400004, Tomball

90057

Matrix Clinical Research Site Number : 8400011, Los Angeles

90274

Peninsula Research Associates Site Number : 8400001, Rolling Hills Estates

90720

Collaborative Neuroscience Research Site Number : 8400017, Los Alamitos

000784

Investigational Site Number : 6300002, Guayama

00909

Investigational Site Number : 6300001, San Juan

00918

Investigational Site Number : 6300003, San Juan

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY